Given mTOR’s involvement in regulating metabolism, mTOR inhibitors like rapamycin have also been explored for metabolic disorders such as type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), where they may improve insulin sensitivity, lipid metabolism, and reduce inflammation. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.